Core Viewpoint - Doximity reported better-than-expected Q3 results but provided lower revenue guidance for Q4 and full-year 2026, leading to a significant drop in stock price during after-hours trading [2][3][4][6] Financial Performance - Doximity's Q3 revenue reached $185.05 million, exceeding estimates of $182.20 million, representing a 10% year-over-year increase [2] - Adjusted earnings for the quarter were 46 cents per share, slightly above the expected 45 cents per share [2] User Engagement and Product Development - The company reported over one million quarterly active prescribers and a record 720,000 users for its workflow products, indicating strong user engagement [3] - Doximity's AI products have gained traction, with over 300,000 users, enhancing the platform's utility [3] Future Guidance - For Q4, Doximity expects revenue between $143 million and $144 million, below the consensus estimate of $150.23 million [4] - The full-year 2026 revenue guidance was narrowed to a range of $642.5 million to $643.5 million from a previous range of $640 million to $646 million [4] Share Repurchase Program - The board of Doximity authorized a share repurchase program to buy back up to $500 million of the company's common stock [4] Stock Performance - Following the earnings report and lowered guidance, Doximity's stock fell by 33.22% in after-hours trading, with shares priced at $22.25 [6]

Revenue and Growth - Revenue for the three months ended December 31, 2025, was $185.1 million, a 10% increase from $168.6 million in the same period of 2024[140] - For the nine months ended December 31, 2025, revenue reached $499.5 million, reflecting a 16% growth compared to $432.1 million in 2024[140] - Revenue for the three months ended December 31, 2025 increased by $16.5 million (10%) compared to the same period in 2024, primarily driven by a $13.1 million increase in subscription revenue[172] - Subscription revenue for the nine months ended December 31, 2025 increased by $60.9 million, with $15.4 million from new subscription customers and $45.5 million from existing customers[172] - Approximately 95% of the company's revenue for the three and nine months ended December 31, 2025 was derived from subscription customers[172] Profitability and Income - Net income for the three months ended December 31, 2025, was $61.6 million, down from $75.2 million in 2024, while adjusted EBITDA was $111.4 million, up from $102.0 million[140] - Net income for the three months ended December 31, 2025 was $61.6 million, a decrease of $13.6 million (18%) compared to the same period in 2024[170] - Gross profit for the three months ended December 31, 2025 was $166.4 million, an increase of $11.9 million (8%) compared to the same period in 2024[172] Customer Metrics - The number of customers with trailing 12-month subscription revenue greater than $500,000 increased to 126 in 2025 from 115 in 2024, accounting for approximately 84% of total revenue[143] - The net revenue retention rate decreased to 112% in 2025 from 117% in 2024, indicating a slight decline in revenue growth from existing customers[145] Expenses - Research and development expenses are expected to increase as the company continues to grow its platform and product offerings[163] - Research and development expenses for the three months ended December 31, 2025 increased by $12.2 million (54%) compared to the same period in 2024, driven by stock-based compensation and personnel costs[174] - Sales and marketing expenses for the three months ended December 31, 2025 increased by $3.7 million (10%) compared to the same period in 2024, primarily due to stock-based compensation[177] - General and administrative expenses for the three months ended December 31, 2025 increased by $4.1 million (30%) compared to the same period in 2024, driven by legal expenses and stock-based compensation[179] - Total operating expenses for the nine months ended December 31, 2025 were $258.5 million, an increase of $46.9 million (22%) compared to the same period in 2024[170] Cash Flow and Financial Position - Free cash flow for the nine months ended December 31, 2025, was $210.2 million, compared to $169.8 million in 2024, demonstrating improved cash generation[154] - Net cash provided by operating activities for the nine months ended December 31, 2025, was $216.9 million, an increase from $174.8 million in the same period in 2024[193][194] - Cash provided by investing activities was $9.2 million for the nine months ended December 31, 2025, primarily from marketable securities[196] - Cash used in financing activities was $370.9 million for the nine months ended December 31, 2025, mainly due to common stock repurchases of $341.1 million[198] - As of December 31, 2025, the company had cash and cash equivalents and marketable securities totaling $735.1 million[187] Share Repurchase and Taxation - The company repurchased 8,648,145 shares of Class A common stock for an aggregate purchase price of $417.0 million as of December 31, 2025, with $83.0 million remaining authorized for repurchase[188] - The effective income tax rate for the company differs from the U.S. statutory tax rate of 21.0% primarily due to stock-based compensation related tax benefits[168] Other Income and Charges - Other income, net for the three months ended December 31, 2025, decreased by 10% to $8.9 million compared to the same period in 2024, primarily due to lower interest income[182][183] - Other income, net for the nine months ended December 31, 2025, increased by 7% to $27.8 million compared to the same period in 2024, driven by a higher average portfolio balance[184] - Provision for income taxes for the three months ended December 31, 2025, increased by 31% to $19.2 million compared to the same period in 2024[185] - The impairment charge for the nine months ended December 31, 2024, was $2.3 million due to a sublease of the Curative office space in Irving, Texas[181] Business Strategy - The business model focuses on providing digital tools for medical professionals, enhancing productivity and patient care[138] - The company aims to expand its market presence and enhance its product offerings through strategic investments and innovations[139] Market Sensitivity - A hypothetical 100 basis point increase in interest rates would have resulted in a decrease of $4.6 million in the market value of cash equivalents and marketable securities as of December 31, 2025[205]

Financial Performance - Total revenues for Q3 FY2026 reached $185.1 million, representing a 10% increase year-over-year from $168.6 million[5] - Net income for the quarter was $61.6 million, with a margin of 33.3%, down from 44.6% in the same quarter last year[5] - Adjusted EBITDA was $111.4 million, reflecting a 9% year-over-year increase, with an adjusted EBITDA margin of 60.2%[5] - The company reported a diluted net income per share of $0.31, down from $0.37 in the same quarter last year[5] - Net income for Q3 2025 was $61,558, a decrease of 18.2% from $75,196 in Q3 2024[15] - Non-GAAP gross profit for Q3 2025 was $111,396, representing a gross margin of 60.2%, compared to 60.5% in Q3 2024[20] - Total revenue for Q3 2025 was $185,053, up from $168,603 in Q3 2024, reflecting a growth of 9.5%[20] - Adjusted EBITDA for Q3 2025 was $111,396, compared to $102,038 in Q3 2024, indicating a year-over-year increase of 9.3%[20] - GAAP operating income for Q3 2025 was $71,896,000, down from $79,925,000 in Q3 2024, indicating a decline of 10.4%[22] - Non-GAAP net income margin for Q3 2025 was 49.3%, down from 54.2% in Q3 2024[22] Cash Flow and Assets - Operating cash flow for the quarter was $60.9 million, a decrease of 7% year-over-year, while free cash flow was $58.5 million, down 8%[5] - Free cash flow for the nine months ended December 31, 2025, was $210,226, an increase from $169,760 in the same period of 2024[20] - Cash and cash equivalents at the end of the period were $64,838, down from $165,270 at the end of Q3 2024[15] - Total assets as of December 31, 2025, were $1.157 billion, down from $1.264 billion as of March 31, 2025[11] Guidance and Stock Repurchase - Doximity updated its revenue guidance for Q4 FY2026 to between $143 million and $144 million, and for the full fiscal year to between $642.5 million and $643.5 million[5] - The company authorized a stock repurchase program of up to $500 million for Class A common stock, with no expiration date[4] Research and Development - Research and development expenses increased to $34.6 million for the quarter, compared to $22.4 million in the same period last year[13] - Research and development expenses for Q3 2025 were $34,595,000, up from $22,421,000 in Q3 2024, marking a significant increase of 54.2%[21] Customer Metrics - The number of quarterly active prescribers exceeded 1 million, with workflow products reaching a record 720,000 users, and AI products surpassing 300,000 users[3] - The net revenue retention rate is a key metric reflecting customer renewals and expansions, directly tied to revenue growth[19] - The number of customers with trailing 12-month subscription revenue greater than $500,000 is a significant indicator of business scale[19] Expenses - The company incurred stock-based compensation expenses of $33,546 in Q3 2025, up from $19,368 in Q3 2024[20] - Total GAAP cost of revenue for Q3 2025 was $18,701,000, compared to $14,181,000 in Q3 2024, reflecting an increase of 32.9%[21] - Non-GAAP sales and marketing expense for Q3 2025 was $31,197,000, slightly higher than $30,853,000 in Q3 2024, indicating a growth of 1.1%[21]

Core Viewpoint - Doximity, Inc. operates a cloud-based digital platform for medical professionals in the U.S., focusing on collaboration, patient care coordination, virtual visits, and career management, positioning itself as a significant player in the healthcare technology sector [1] Price Target Trends - The consensus price target for Doximity's stock has decreased over the past year, with the average target falling from $60.56 last year to $55.60 last quarter, and further down to $53.50 last month, indicating a more conservative outlook from analysts [2][6] Ownership Structure - Doximity has substantial institutional and insider ownership, with 87.2% of shares held by these entities, which may enhance stock stability and bolster investor confidence [3][6] Analyst Ratings - Doximity has received a Zacks Rank 1 (Strong Buy) upgrade, reflecting optimism regarding its earnings prospects and suggesting potential upward movement in stock price despite the declining consensus price targets [4][6] Market Comparisons - Recent analyses have compared Doximity with other service-oriented companies, focusing on valuation, profitability, and institutional ownership, which aids investors in understanding Doximity's market position and future potential [5]

Market Analysis by covering: Phreesia Inc, Doximity Inc, Waystar Holding Corp. Read 's Market Analysis on Investing.com ...

Core Insights - Advancements in artificial intelligence (AI) are significantly enhancing patient care, reducing healthcare costs, and improving outcomes in the medical technology industry [1] - Generative AI is transitioning from a conceptual promise to practical applications in medical technology [1] Industry Developments - AI is expediting all phases of research and development, including generative design, virtual testing, clinical trials, and regulatory documentation [2] - The FDA is promoting the development of innovative medical devices that incorporate AI [2] Company Performance: Tempus AI (TEM) - Tempus has seen a stock increase of 27.2% over the past year, while Doximity's stock has declined by 32.8% [6] - The company is developing advanced AI algorithms and diagnostic software, collaborating with Northwestern University's Abrams Center for Alzheimer's research [7] - Tempus has received two FDA 510(k) clearances for its cardiac imaging platform and ECG-Low EF software [8] - In Q3 2025, Tempus achieved positive adjusted EBITDA of $1.5 million, with gross profit rising to $209.9 million, a 98.4% year-over-year increase [11] - EPS for 2025 is projected to be a loss of 64 cents, reflecting a 59.5% improvement from 2024 [15] Company Performance: Doximity (DOCS) - Doximity is well-positioned for AI adoption, embedding AI across its workflows and benefiting from a recent acquisition of Pathway Medical Inc. [9][13] - The company reported a 55% adjusted EBITDA margin and a 39% net income margin in fiscal 2025, with $267 million in free cash flow [14] - EPS for fiscal 2026 is projected to be $1.56, indicating a 9.9% improvement from fiscal 2025 [16] Valuation Comparison - Tempus has a forward 12-month price-to-sales (P/S) ratio of 7.24, while Doximity's is 10.38, indicating Doximity is trading at a premium [17] Conclusion - Doximity appears better positioned than Tempus, with deep AI integration, strategic acquisitions, and strong profitability metrics [18] - Tempus is recognized for its expanding AI capabilities and recent profitability milestone, indicating long-term potential in precision medicine [19]

Company Performance - Doximity (DOCS) closed at $38.96, down 3.56% from the previous trading session, underperforming the S&P 500's gain of 0.41% [1] - The company's shares have decreased by 8.66% over the past month, while the Medical sector lost 0.74% and the S&P 500 gained 0.38% during the same period [1] Upcoming Earnings - Doximity is set to release its earnings report on February 5, 2026, with an expected EPS of $0.44, reflecting a 2.22% decline compared to the same quarter last year [2] - Revenue is anticipated to be $181.03 million, which is a 7.37% increase from the prior-year quarter [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $1.56 per share, with revenue expected to reach $645.29 million, indicating increases of 9.86% and 13.13% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Doximity are crucial as they indicate shifts in near-term business trends, with positive revisions suggesting confidence in the company's performance [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Doximity as 1 (Strong Buy), reflecting strong potential for outperformance [6] Valuation Metrics - Doximity has a Forward P/E ratio of 25.82, which is lower than the industry average of 27.99, indicating a valuation discount [7] - The company also has a PEG ratio of 1.36, compared to the industry average PEG ratio of 2.33, suggesting favorable growth prospects relative to its valuation [7] Industry Context - The Medical Info Systems industry, which includes Doximity, holds a Zacks Industry Rank of 82, placing it in the top 34% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1, highlighting the strength of the Medical Info Systems sector [8]

Core Viewpoint - Doximity (DOCS) has received a Zacks Rank 1 (Strong Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in a company's earnings picture, with the consensus of EPS estimates from analysts being a key component [1][2]. - An increase in earnings estimates is strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4]. Business Improvement Indicators - The upgrade in Doximity's rating suggests an improvement in the company's underlying business, which is expected to lead to higher stock prices as investors respond positively [5][10]. - For the fiscal year ending March 2026, Doximity is projected to earn $1.56 per share, with a 2% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of stocks covered by Zacks receive a "Strong Buy" rating, indicating superior earnings estimate revisions and potential for market-beating returns [9][10].

Key Points Medicare will no longer cover telemedicine services for many patients. This change will affect Teladoc Health, which was already struggling. Doximity might be less affected, but its prospects look dim as well. 10 stocks we like better than Teladoc Health › Telehealth services are convenient. There is nothing quite like being able to get some medical care, albeit virtual, from the comfort of one's home. Telehealth likely saves physicians and patients time and money. However, none of t ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. U.S. equity markets experienced a quarter shaped by optimism around potential monetary easing and caution related to economic growth and valuations. Early gains were driven by strong AI-related earnings and the US Federal Reserve’s rate cut in October. However, market sentiment cooled later in the quarter due to mixed signals from the Fed regardi ...